Detalhe da pesquisa
1.
Class-sparing regimens for initial treatment of HIV-1 infection.
N Engl J Med
; 358(20): 2095-106, 2008 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18480202
2.
Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.
AIDS
; 21(3): 325-33, 2007 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-17255739
3.
Phase I/II trial of the anti-HIV activity of mifepristone in HIV-infected subjects ACTG 5200.
J Acquir Immune Defic Syndr
; 53(4): 491-5, 2010 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20130470
4.
Effect of highly active antiretroviral therapy on viral burden in the lungs of HIV-infected subjects.
J Infect Dis
; 197(1): 109-16, 2008 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18171293
5.
Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).
J Acquir Immune Defic Syndr
; 45(2): 193-200, 2007 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17527093
6.
Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals.
Antimicrob Agents Chemother
; 49(8): 3373-81, 2005 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-16048950